Uptake of cervical cancer screening and associated factors among human immune virus positive women attending antiretroviral therapy clinic in public health facilities, Northeast Ethiopia, 2022: A cross-sectional study.
Yemane Eshetu BekaluYemane Eshetu BekaluAmare Workie GashuPublished in: SAGE open medicine (2024)
The magnitude of cervical cancer screening was 19.2% (15.7%-22.9%). Multiparity, bad obstetric history, hearing about cervical cancer, recommendations from medical professionals, duration of antiretroviral therapy >10 years, a family record of cervical cancer, and knowing cervical cancer were revealed to be predictors of testing for cervical cancer.
Keyphrases
- cervical cancer screening
- antiretroviral therapy
- public health
- hiv infected
- human immunodeficiency virus
- hiv infected patients
- hiv aids
- hiv positive
- healthcare
- primary care
- pregnant women
- physical activity
- type diabetes
- risk factors
- polycystic ovary syndrome
- adipose tissue
- hepatitis c virus
- tertiary care
- men who have sex with men
- pluripotent stem cells